King's College London

Research portal

Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet

Research output: Contribution to journalReview article

Standard

Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification : A Consensus Statement From the COST Action EuroSoftCalcNet. / COST Action Consortium EuroSoftCalcNet.

In: Frontiers in Cardiovascular Medicine, Vol. 5, 196, 18.01.2019.

Research output: Contribution to journalReview article

Harvard

COST Action Consortium EuroSoftCalcNet 2019, 'Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet', Frontiers in Cardiovascular Medicine, vol. 5, 196. https://doi.org/10.3389/fcvm.2018.00196

APA

COST Action Consortium EuroSoftCalcNet (2019). Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet. Frontiers in Cardiovascular Medicine, 5, [196]. https://doi.org/10.3389/fcvm.2018.00196

Vancouver

COST Action Consortium EuroSoftCalcNet. Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet. Frontiers in Cardiovascular Medicine. 2019 Jan 18;5. 196. https://doi.org/10.3389/fcvm.2018.00196

Author

COST Action Consortium EuroSoftCalcNet. / Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification : A Consensus Statement From the COST Action EuroSoftCalcNet. In: Frontiers in Cardiovascular Medicine. 2019 ; Vol. 5.

Bibtex Download

@article{32270a613814404fa3d67ee781de27ba,
title = "Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet",
abstract = "The physicochemical deposition of calcium-phosphate in the arterial wall is prevented by calcification inhibitors. Studies in cohorts of patients with rare genetic diseases have shed light on the consequences of loss-of-function mutations for different calcification inhibitors, and genetic targeting of these pathways in mice have generated a clearer picture on the mechanisms involved. For example, generalized arterial calcification of infancy (GACI) is caused by mutations in the enzyme ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (eNPP1), preventing the hydrolysis of ATP into pyrophosphate (PPi). The importance of PPi for inhibiting arterial calcification has been reinforced by the protective effects of PPi in various mouse models displaying ectopic calcifications. Besides PPi, Matrix Gla Protein (MGP) has been shown to be another potent calcification inhibitor as Keutel patients carrying a mutation in the encoding gene or Mgp-deficient mice develop spontaneous calcification of the arterial media. Whereas PPi and MGP represent locally produced calcification inhibitors, also systemic factors contribute to protection against arterial calcification. One such example is Fetuin-A, which is mainly produced in the liver and which forms calciprotein particles (CPPs), inhibiting growth of calcium-phosphate crystals in the blood and thereby preventing their soft tissue deposition. Other calcification inhibitors with potential importance for arterial calcification include osteoprotegerin, osteopontin, and klotho. The aim of the present review is to outline the latest insights into how different calcification inhibitors prevent arterial calcification both under physiological conditions and in the case of disturbed calcium-phosphate balance, and to provide a consensus statement on their potential therapeutic role for arterial calcification.",
keywords = "arterial calcification, fetuin, gla proteins, klotho, osteopontin, osteoprotegerin, pyrophosphate",
author = "{COST Action Consortium EuroSoftCalcNet} and Magnus B{\"a}ck and Tamas Aranyi and Cancela, {M. Leonor} and Miguel Carracedo and Nat{\'e}rcia Concei{\cc}{\~a}o and Georges Leftheriotis and Vicky Macrae and Ludovic Martin and Yvonne Nitschke and Andreas Pasch and Daniela Quaglino and Frank Rutsch and Catherine Shanahan and Victor Sorribas and Flora Szeri and Pedro Valdivielso and Olivier Vanakker and Herv{\'e} Kempf",
year = "2019",
month = "1",
day = "18",
doi = "10.3389/fcvm.2018.00196",
language = "English",
volume = "5",
journal = "Frontiers in Cardiovascular Medicine",
issn = "2297-055X",
publisher = "Frontiers Media S.A.",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification

T2 - A Consensus Statement From the COST Action EuroSoftCalcNet

AU - COST Action Consortium EuroSoftCalcNet

AU - Bäck, Magnus

AU - Aranyi, Tamas

AU - Cancela, M. Leonor

AU - Carracedo, Miguel

AU - Conceição, Natércia

AU - Leftheriotis, Georges

AU - Macrae, Vicky

AU - Martin, Ludovic

AU - Nitschke, Yvonne

AU - Pasch, Andreas

AU - Quaglino, Daniela

AU - Rutsch, Frank

AU - Shanahan, Catherine

AU - Sorribas, Victor

AU - Szeri, Flora

AU - Valdivielso, Pedro

AU - Vanakker, Olivier

AU - Kempf, Hervé

PY - 2019/1/18

Y1 - 2019/1/18

N2 - The physicochemical deposition of calcium-phosphate in the arterial wall is prevented by calcification inhibitors. Studies in cohorts of patients with rare genetic diseases have shed light on the consequences of loss-of-function mutations for different calcification inhibitors, and genetic targeting of these pathways in mice have generated a clearer picture on the mechanisms involved. For example, generalized arterial calcification of infancy (GACI) is caused by mutations in the enzyme ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (eNPP1), preventing the hydrolysis of ATP into pyrophosphate (PPi). The importance of PPi for inhibiting arterial calcification has been reinforced by the protective effects of PPi in various mouse models displaying ectopic calcifications. Besides PPi, Matrix Gla Protein (MGP) has been shown to be another potent calcification inhibitor as Keutel patients carrying a mutation in the encoding gene or Mgp-deficient mice develop spontaneous calcification of the arterial media. Whereas PPi and MGP represent locally produced calcification inhibitors, also systemic factors contribute to protection against arterial calcification. One such example is Fetuin-A, which is mainly produced in the liver and which forms calciprotein particles (CPPs), inhibiting growth of calcium-phosphate crystals in the blood and thereby preventing their soft tissue deposition. Other calcification inhibitors with potential importance for arterial calcification include osteoprotegerin, osteopontin, and klotho. The aim of the present review is to outline the latest insights into how different calcification inhibitors prevent arterial calcification both under physiological conditions and in the case of disturbed calcium-phosphate balance, and to provide a consensus statement on their potential therapeutic role for arterial calcification.

AB - The physicochemical deposition of calcium-phosphate in the arterial wall is prevented by calcification inhibitors. Studies in cohorts of patients with rare genetic diseases have shed light on the consequences of loss-of-function mutations for different calcification inhibitors, and genetic targeting of these pathways in mice have generated a clearer picture on the mechanisms involved. For example, generalized arterial calcification of infancy (GACI) is caused by mutations in the enzyme ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (eNPP1), preventing the hydrolysis of ATP into pyrophosphate (PPi). The importance of PPi for inhibiting arterial calcification has been reinforced by the protective effects of PPi in various mouse models displaying ectopic calcifications. Besides PPi, Matrix Gla Protein (MGP) has been shown to be another potent calcification inhibitor as Keutel patients carrying a mutation in the encoding gene or Mgp-deficient mice develop spontaneous calcification of the arterial media. Whereas PPi and MGP represent locally produced calcification inhibitors, also systemic factors contribute to protection against arterial calcification. One such example is Fetuin-A, which is mainly produced in the liver and which forms calciprotein particles (CPPs), inhibiting growth of calcium-phosphate crystals in the blood and thereby preventing their soft tissue deposition. Other calcification inhibitors with potential importance for arterial calcification include osteoprotegerin, osteopontin, and klotho. The aim of the present review is to outline the latest insights into how different calcification inhibitors prevent arterial calcification both under physiological conditions and in the case of disturbed calcium-phosphate balance, and to provide a consensus statement on their potential therapeutic role for arterial calcification.

KW - arterial calcification

KW - fetuin

KW - gla proteins

KW - klotho

KW - osteopontin

KW - osteoprotegerin

KW - pyrophosphate

UR - http://www.scopus.com/inward/record.url?scp=85063615270&partnerID=8YFLogxK

U2 - 10.3389/fcvm.2018.00196

DO - 10.3389/fcvm.2018.00196

M3 - Review article

AN - SCOPUS:85063615270

VL - 5

JO - Frontiers in Cardiovascular Medicine

JF - Frontiers in Cardiovascular Medicine

SN - 2297-055X

M1 - 196

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454